Eris Lifesciences (ERIS) Fundamentals 2026 — P/E 31.7x, Revenue Analysis | SniperIQ
Eris Lifesciences (ERIS) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹19,973 Crore, trading at ₹1440.45 on the BSE. This SniperIQ fundamentals page covers Eris Lifesciences's valuation (P/E 31.7x, P/B 5.0x), profitability (net margin 19.8%), revenue (₹3,129 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Eris Lifesciences's market cap?
Eris Lifesciences (ERIS) has a market capitalization of approximately ₹19,973 Crore, trading at ₹1440.45 on the BSE. Market cap moves with the live share price.
What is Eris Lifesciences's P/E ratio?
Eris Lifesciences's trailing twelve-month P/E ratio is 31.7x, with a price-to-book (P/B) of 5.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Eris Lifesciences?
Eris Lifesciences runs a net profit margin of 19.8%, a gross margin of 47.9%, and an operating margin of 26.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Eris Lifesciences generate?
Eris Lifesciences reported revenue of ₹3,129 Crore for fiscal year 2026, with net income of ₹620 Crore and earnings per share (EPS) of 45.33. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Eris Lifesciences pay a dividend?
Eris Lifesciences offers a trailing dividend yield of about 0.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Eris Lifesciences financially healthy?
Eris Lifesciences carries a debt-to-equity ratio of 0.60x and a current ratio of 0.74x, with a market beta of -0.11. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Eris Lifesciences a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Eris Lifesciences (ERIS) the key facts are: market cap ₹19,973 Crore, P/E 31.7x, revenue ₹3,129 Crore, 52-week range 1237.9-1887.65. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Eris Lifesciences's full fundamentals live
Get Eris Lifesciences's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.